ETS-Domain Transcription Factor Elk-1 Regulates Stemness Genes in Brain Tumors and CD133+ BrainTumor-Initiating Cells

dc.contributor.authorSogut, Melis Savasan
dc.contributor.authorVenugopal, Chitra
dc.contributor.authorKandemir, Basak
dc.contributor.authorDag, Ugur
dc.contributor.authorMahendram, Sujeivan
dc.contributor.authorSingh, Sheila
dc.contributor.authorGulfidan, Gizem
dc.contributor.authorArga, Kazim Yalcin
dc.contributor.authorYilmaz, Bayram
dc.contributor.authorKurnaz, Isil Aksan
dc.contributor.orcID0000-0003-1909-5778en_US
dc.contributor.pubmedID33672811en_US
dc.date.accessioned2022-09-15T08:29:43Z
dc.date.available2022-09-15T08:29:43Z
dc.date.issued2021
dc.description.abstractElk-1, a member of the ternary complex factors (TCFs) within the ETS (E26 transformation-specific) domain superfamily, is a transcription factor implicated in neuroprotection, neurodegeneration, and brain tumor proliferation. Except for known targets, c-fos and egr-1, few targets of Elk-1 have been identified. Interestingly, SMN, SOD1, and PSEN1 promoters were shown to be regulated by Elk-1. On the other hand, Elk-1 was shown to regulate the CD133 gene, which is highly expressed in brain-tumor-initiating cells (BTICs) and used as a marker for separating this cancer stem cell population. In this study, we have carried out microarray analysis in SH-SY5Y cells overexpressing Elk-1-VP16, which has revealed a large number of genes significantly regulated by Elk-1 that function in nervous system development, embryonic development, pluripotency, apoptosis, survival, and proliferation. Among these, we have shown that genes related to pluripotency, such as Sox2, Nanog, and Oct4, were indeed regulated by Elk-1, and in the context of brain tumors, we further showed that Elk-1 overexpression in CD133+ BTIC population results in the upregulation of these genes. When Elk-1 expression is silenced, the expression of these stemness genes is decreased. We propose that Elk-1 is a transcription factor upstream of these genes, regulating the self-renewal of CD133+ BTICs.en_US
dc.identifier.eissn2075-4426en_US
dc.identifier.endpage28en_US
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85101225734en_US
dc.identifier.startpage1en_US
dc.identifier.urihttps://www.mdpi.com/2075-4426/11/2/125
dc.identifier.urihttp://hdl.handle.net/11727/7761
dc.identifier.volume11en_US
dc.identifier.wos000622734200001en_US
dc.language.isoengen_US
dc.relation.isversionof10.3390/jpm11020125en_US
dc.relation.journalJOURNAL OF PERSONALIZED MEDICINEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectETSen_US
dc.subjectElk-1en_US
dc.subjectstem cellen_US
dc.subjectmicroarrayen_US
dc.subjectbrain-tumor-initiating cell (BTIC)en_US
dc.titleETS-Domain Transcription Factor Elk-1 Regulates Stemness Genes in Brain Tumors and CD133+ BrainTumor-Initiating Cellsen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
jpm-11-00125-v2.pdf
Size:
2.69 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: